Abstract
The Australian Lung Cancer Conference (ALCC) took place in Adelaide, Australia, 23–25 August 2012, hosted by the Australian Lung Foundation. Its theme was translating advances into clinical practice, and featured a wide range of presentations from local and international experts, including medical and radiation oncologists, thoracic surgeons, epidemiologists, basic scientists and pathologists (both conventional and the increasingly important molecular pathologists). It is a testament to the quality of Australian cancer research, and commitment to service delivery, that such an impressive faculty could gather and devote three full days to a wide range of topics involving basic and applied research in prevention, diagnosis and treatment of thoracic malignancies. Thanks are also owing to the sponsors, including multiple pharmaceutical companies, reflecting the increasing scope for targeted systemic therapies in advanced non-small-cell lung cancer, the focus of this article.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
